Long-Term Follow-up of Patients With Multiple Myeloma Who Received Allogeneic Hematopoietic Stem Cell Transplantation
Michèle L. Donato(The University of Texas Health Science Center at Houston), Scott D. Rowley(Johns Hopkins Hospital), Phyllis McKiernan(Hackensack University Medical Center), David S. Siegel(Hackensack Meridian Health), Andrew L. Pecora(Hackensack University Medical Center), Themba Nyirenda(Hackensack University Medical Center), Melissa Baker(Hackensack University Medical Center), Anthony R. Mato(University of Pennsylvania), Joshua R. Richter(Hackensack University Medical Center), David H. Vesole(Hackensack University Medical Center)
Cited by 1
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION
|British Journal of Haematology|1998|1.5k
Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
|Cancer Cell|2014|1k